Vendor, Exeter, NH
Cytokind Inc.
UEI ESXSVJEX6E33, CAGE 8SF56
1 award and -$604,585 obligated between January 16, 2024 and January 16, 2024, 0% under full and open competition, against 100.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | -$604,585 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | -$604,585 |
How it wins
Awards by competition, set-aside and type.
| Competed Under SAP | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50122C00064Definitive Contract, January 16, 2024, Competed Under SAP, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Cytokind: the Overall Objective of This Contract Is to Provide Clinical Validation for the Treatment of Covid with NB-UVB Therapy. a SubmissNAICS 541715, PSC AN15 | -$604,585 |
- Places of performance
- New Hampshire
- Product and service codes
- AN15 Health R&D Services; Health Care Services; Expenses For R&D Facilities And Major Equipment
- Transactions
- 1 across 1 awards